Targetability of human disease genes

Current Drug Discovery Technologies

Volumn 4, Issue 1, 2007, Pages 48-58

  Sakharkar, Meena K ^a   Sakharkar, Kishore R ^b  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Disease genes; Drugs; Model organisms; Target

Indexed keywords

ACETAZOLAMIDE; AMIODARONE; BENAZEPRIL; BETAXOLOL; CARVEDILOL; CONIVAPTAN; DESIPRAMINE; DOCETAXEL; DONEPEZIL; ENALAPRIL; FENOLDOPAM; FLUTAMIDE; FOSINOPRIL; GALANTAMINE; IMATINIB; ISOPRENALINE; LABETALOL; LEVOBUNOLOL; LISINOPRIL; LOSARTAN; MALATHION; PACLITAXEL; PRALIDOXIME; PYRIDOSTIGMINE; RIVASTIGMINE; SEVOFLURANE; TESTOSTERONE; UNINDEXED DRUG; VALSARTAN; ZONISAMIDE;

BIOINFORMATICS; COMPUTER MODEL; DRUG TARGETING; GENE SEQUENCE; GENE TARGETING; PRIORITY JOURNAL; PROMOTER REGION; RETINOL DEFICIENCY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

DATABASES, GENETIC; DRUG DELIVERY SYSTEMS; DRUG DESIGN; GENETIC DISEASES, INBORN; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; GENOMICS; HUMANS; MODELS, GENETIC; PHARMACOGENETICS;

EID: 34447134123     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016307781115494     Document Type: Review

References (50)

1. Yaspo M.L.: Taking a functional genomics approach in molecular medicine. Trends Mol. Med. 7(11), 494, (2001).
2. Kiyosawa H., Kawashima T., Silva D., Petrovsky N., Hasegawa Y., Sakai K., Hayashizaki Y.: Systematic genome-wide approach to positional candidate cloning for identification of novel human disease genes. Intern. Med. J. 34(3), 79, (2004).
3. Hamosh A., Scott A.F., Amberger J.S., Bocchini C.A., McKusick V.A.: Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res. 33, D514, (2005).
4. Chien S. Reiter L.T., Bier E., Gribskov M.: Homophila: human disease gene cognates in Drosophila. Nucleic Acids Res. 30, 149, (2002).
5. Maglott D., Ostell J., Pruitt K.D., Tatusova T.: Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res. 35, D26, (2007)
6. Stenson P.D., Ball E.V., Mort M., Phillips A.D., Shiel J.A., Thomas N.S., Abeysinghe S., Krawczak M., et al.: Human Gene Mutation Database (HGMD): 2003 update. Hum. Mutat. 21, 577, (2003)
7. Safran M., Solomon I., Shmueli O., Lapidot M., Shen-Orr S., Adato A., Ben-Dor U., Esterman N., et al.: GeneCards 2002: towards a complete, object-oriented, human gene compendium. Bioinformatics 18, 1542, (2002).
8. Lopez-Bigas N., Ouzounis C.A.: Genome-wide identification of genes likely to be involved in human genetic disease. Nucleic Acids Res., 32, 3108, (2005).
9. Searls D.B.: Data integration: challenges for drug discovery. Nat. Rev. Drug Discov. 4, 45, (2005).
10. Loging W., Harland L., Williams-Jones B.: High-throughput electronic biology: mining information for drug discovery. Nat. Rev. Drug Discov. 6(3), 220, (2007).
11. Hajduk P.J., Huth J.R., Tse C.: Predicting protein druggability. Drug Discov. Today. 10, 1675, (2005).
12. Hopkins A.L., Groom C.R.: The druggable genome. Nat. Rev. Drug Discov. 1, 727, (2002).
13. Russ A.P., Lampel S.: The druggable genome: an update. Drug Discov. Today 10, 1607, (2005).
14. Brinkman R.R., Dube M.P., Rouleau GA, Orr AC, Samuels ME: Human monogenic disorders - a source of novel drug targets. Nat. Rev. Genet. 7(4), 249, (2006).
15. Wishart D.S., Knox C., Guo A.C., Shrivastava S., Hassanali M., Stothard P., Chang Z., Woolsey J.: DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 34, D668, (2006).
16. Brookes AJ.: The essence of SNPs. Gene 234(2): 177, (1999).
17. Hoehe M.R., Timmermann B., Lehrach, H.: Human inter-individual DNA sequence variation in candidate genes, drug targets, the importance of haplotypes and pharmacogenomics. Curr. Pharm. Biotechnol. 4(6), 351, (2003).
18. Maitland M.L., DiRienzo A., Ratain M.J.: Interpreting Disparate Responses to Cancer Therapy: The Role of Human Population Genetics. J. Clin. Oncol. 24(14), 2151, (2006).
19. Masood E.: As consortium plans free SNP map of human genome. Nature 398, 545, (1999).
20. Vitkup D., Sander C., Church G.M.: The amino-acid mutational spectrum of human genetic disease. Genome Biol. 4, R72, (2003).
21. Wang Z., Moult J.: SNPs, protein structure, and disease. Hum. Mutat. 17, 263, (2001).
22. Seelinger M.W., Biesalski H.K., Wissinger B., Gollnick H., Gielen S., Frank J., Beck S., Zrenner E.: Phenotype in retinol deficiency due to a hereditary defect in the retinol binding protein synthesis. Invest. Opthalmol. Vis. Sci. 40, 3, (1999).
23. Robert B.: Hash Hereditary Hemochromatosis J. Am. Board Fam. Pract. 14, 266, (2001).
24. Kim S., Misra A.: SNP Genotyping: Technologies and Biomedical Applications. Annu. Rev. Biomed. Eng. Mar 28, (2007).
25. Delrieu O, Bowman C.: Visualizing gene determinants of disease in drug discovery. Pharmacogenomics 7(3), 311, (2006).
26. Giacomini K.M., Brett C.M., Altman R.B., Benowitz N.L., Dolan M.E., Flockhart D.A., Johnson J.A., Hayes D.F., et al.: Pharmacogenetics Research Network. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin. Pharmacol. Ther. 81(3), 328, (2007).
27. McLeod H.L., Evans W.E.: Pharmacogenomics: unlocking the human genome for better drug therapy. Annu. Rev. Pharmacol. Toxicol. 41,101, (2001).
28. Evans W.E., Johnson J.A.: Pharmacogenomics: The Inherited Basis for Inter individual Differences in Drug Response. Annu. Rev. Genomics Hum. Genet. 2, 9, (2001).
29. Shah R.R.: Mechanistic basis of adverse drug reactions: the perils of inappropriate dose schedules. Expert Opin. Drug Saf. 4(1), 103, (2005).
30. Rane A.: Postgenomic prospects of success in drug development and pharmacotherapy. Pharmacogenomics J. 1(1), 6, (2001).
31. Bosch T.M., Meijerman I., Beijnen J.H., Schellens J.H.: Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin. Pharmacokinet. 45(3), 253, (2006).
32. Lai E.: Application of SNP technologies in medicine: lessons learned and future challenges. Genome Res. 11(6), 927, (2001).
33. Klein T.E., Chang J.T., Cho M.K., Easton K.L., Fergerson R., Hewett M., Lin Z., Liu Y., et al.: Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenomics J. 1, 167, (2001).
34. Masood E.: As consortium plans free SNP map of human genome. Nature 398, 545, (1999).
35. Reich D.E., Lander E.S.: On the allelic spectrum of human disease. Trends Genet. (2001).
36. Sams-Dodd F.: Drug discovery: selecting the optimal approach. Drug Discov. Today. 9, 465, (2006).
37. Peltonen L., McKusick V.A.: Genomics and medicine. Dissecting human disease in the postgenomic. era. Science 16, 291(5507), 1224, (2001).
38. Kubinyi H.: Drug Research: Myth, hype and reality. Nat. Rev. Drug Discov. 2, 665, (2003).
39. Gonzalez-Ruiz D., Gohlke H.: Targeting protein-protein interactions with small molecules: challenges and perspectives for computational binding epitope detection and ligand finding. Curr. Med. Chem. 13, 2607, (2006).
40. Kane J.M., Malhotra A.: The future of pharmacotherapy for schizophrenia. World Psychiatry 2(2), 81, (2003).
41. Wright A.F., Hastie N.D.: Complex genetic diseases: controversy over the Croesus code. Genome Biol. 2(8), (2001).
42. Zheng C., Han L., Yap C.W., Xie B., Chen Y.: Progress and problems in the exploration of therapeutic targets. Drug Discov. Today. 11(9-10), 412, (2006).
43. Lindsay M.A.: Target discovery. Nat. Rev. Drug Discov. 10, 831, (2003).
44. Sergey I.: De-risking the Discovery and Development of New Drugs from Bench to Clinic. Curr. Top. Med. Chem. 5(11), 1031, (2005).
45. Huang H., Winter E.E., Wang H., Weinstock K.G., Xing H., Goodstadt L., Stenson P.D., Cooper D.N., et al. Evolutionary conservation and selection of human disease gene orthologs in the rat and mouse genomes. Genome Biol. 5(7), R47, (2004).
46. O'Brien K.P., Westerlund I., Sonnhammer E.L.: Ortho Disease: a database of human disease orthologs. Hum. Mutat. 24, 112, (2004).
47. Zambrowicz B.P., Sands A.T.: Knockouts model the 100 best-selling drugs - will they model the next 100? Nat. Rev. Drug Discov. 2, 38, (2003).
48. Ratcliffe H.L., Luginbuhl, H.: The domestic pig: A model for experimental atherosclerosis. Atherosclerosis 13, 133, (1971).
49. Rocha D., Plastow, G.: Commercial pigs: an untapped resource for human obesity research? Drug Discov. Today 11, 475, (2006).
50. Muqit M.M., Feany, M.B.: Modelling neurodegenerative diseases in Drosophila: a fruitful approach? Nat. Rev. Neurosci. 3, 237, (2002).